Researchers found that a prime-boost strategy using different subtypes of H5N1 vaccines significantly boosted immune responses in individuals with prior exposure. Additionally, an intradermal approach to delivering the vaccine showed promise but did not improve the immune response. These findings suggest pre-pandemic priming with exist...
A new study found that an investigational therapy reduced allergy symptoms in adults for at least a year after just six injections of the major ragweed allergen, Amb a 1, coupled to a unique DNA sequence. The therapy showed promise in reducing symptoms and improving quality-of-life scores compared to standard immunotherapy.
A comprehensive mouse study provides new clues about the virulence of the 1918 influenza virus. The research found that a hyperactive immune response triggered by the virus may contribute to its exceptional lethality. Understanding this phenomenon is crucial for developing therapies against future flu pandemics.
A clinical trial shows that islet transplantation using the Edmonton Protocol can dramatically benefit certain patients with severe complications of Type 1 diabetes. The procedure has promising implications for treating this autoimmune disease, which affects an estimated 21 million Americans.
A clinical trial has demonstrated the efficacy of an H9N2 avian flu vaccine combined with an adjuvant in generating a strong antibody response in humans. The results suggest that even low doses of the vaccine can provide protection, making it a promising tool in pandemic prevention.
The NIAID has awarded five grants totaling up to $4 million to fund the development of products that eliminate radioactive materials from the human body. The goal is to accelerate the development of previously identified compounds into effective products for licensing in the strategic national stockpile.
A promising new TB drug candidate, SQ109, has been cleared for Phase I clinical trials following a successful public-private partnership between NIAID and Sequella. Developed with extensive support from NIAID, SQ109 holds potential for treating the virtually untreatable disease XDR-TB.
Researchers have developed a live, attenuated H5N1 avian flu vaccine that protected mice and ferrets from deadly infection with naturally occurring H5N1 flu viruses. The vaccine demonstrated cross-protection against different emerging H5N1 virus strains.
A new microchip-based test called FluChip can distinguish among 72 influenza strains in under 12 hours, enhancing global flu surveillance efforts. This technology has the potential to increase laboratory diagnostic capacity and provide critical information on the geographic origin of emerging viruses.
Researchers developed a gamma-irradiated Listeria monocytogenes vaccine that elicits a strong T-cell response and protects against live challenge. The irradiated bacteria stimulate both adaptive and innate immune systems, providing a promising alternative to traditional vaccines.
The Program in Systems Immunology and Infectious Disease Modeling (PSIIM) aims to understand complex biochemical networks regulating interactions between pathogens and human cells. The program employs Simmune software to simulate biological systems, enabling scientists to predict how drugs affect cell behavior and develop new treatments.
A recent study reveals that prion disease infectivity can cause heart damage in mice, with similarities to human amyloid heart disease. The findings have significant implications for the development of new diagnostic tests and treatments for prion diseases.
The National Institute of Allergy and Infectious Diseases (NIAID) has announced the leadership for its newly restructured HIV/AIDS clinical trials networks. The six networks will focus on high-priority research areas, including developing an effective HIV vaccine and conducting translational research for new drug development.
Researchers found that monkeys vaccinated against simian immunodeficiency virus (SIV) survived longer after infection compared to unvaccinated animals. The vaccine regimen preserved memory CD4+ T cells, enabling the animals to live healthier lives.
Advances in HIV care have yielded a total survival benefit of 2.8 million years in the US, saving an additional 137,000 years of life through mother-to-child transmission prevention. The study found that HIV therapies have transformed the disease from a rapidly fatal condition to a controllable one.
A new NIAID study found that a higher dose of flu vaccine significantly increases the immune responses of older adults, providing hope for better protection against seasonal influenza. The trial showed that participants who received a high-dose vaccine had 44-79% higher levels of antibody than those who received the standard dose.
A post-exposure vaccine has been shown to protect monkeys against the deadly Marburg virus. Researchers tested the vaccine in a study involving non-human primates and found it to be highly effective in preventing severe symptoms of the disease.
A new anthrax antitoxin has been designed using a fatty bubble studded with small proteins that can effectively neutralize the toxin. The polyvalent inhibitor showed 10,000 times more potency than unattached peptides and prevented five out of nine rats from becoming ill when given in combination with antibiotics.
Researchers reveal that specific physical and chemical cues guide CD8+ T cells to sites of activation in the lymph node. This discovery provides insight into the fundamental behavior of the immune system and suggests new approaches to vaccine strategies.
Researchers identified a novel disease-causing bacterium in patients with Chronic Granulomatous Disease (CGD), a rare immune disorder. The bacterium, Granulobacter bethesdensis, is part of the Acetobacteraceae family and was found in inflamed lymph nodes.
Researchers have discovered a major gateway for KSHV entry into human cells, suggesting the virus may facilitate its own infectivity by inducing stress responses. This finding has significant implications for understanding Kaposi's sarcoma and developing new treatments.
The H5N1 avian flu vaccine has shown promise in inducing immune responses in healthy adults. Among the 99 participants who received the high-dose vaccine, 54% developed neutralizing antibodies to the vaccine at a serum dilution of 1:40 or greater.
A new study reveals that people with eczema may benefit from smallpox vaccination due to their immune system's overproduction of inflammation-promoting molecules. The research suggests that developing drugs or creams to mimic the action of LL-37 or neutralizing IL-4 and IL-13 could be effective in boosting the immune response.
A new study describes the structure of an H5 protein from a highly pathogenic strain of H5N1 avian influenza virus, comparing it to other pandemic influenza A viruses. The research also discusses a potential route for H5N1 to mutate and acquire human specificity.
Researchers identified a specific set of genes expressed differently in individuals with eosinophilic esophagitis (EE), a chronic disease causing inflammation in the esophagus. The study found that eotaxin-3 levels were significantly higher in EE patients, suggesting potential therapeutic targets.
Researchers have developed hybrid antibodies from chimpanzees and humans that effectively inhibited the spread of vaccinia and variola viruses in test tube experiments. In mice infected with vaccinia virus, the hybrid antibodies proved more effective than anti-vaccinia immune globulin when given two days after virus exposure.
The Strategies for Management of Anti-Retroviral Therapy (SMART) trial found that participants on continuous antiretroviral therapy had significantly lower risk of disease progression compared to those on episodic therapy. The study also revealed increased risks of cardiovascular, kidney, and liver diseases in participants on the drug ...
Leading NIAID researchers explore the complex relationship between influenza viruses and the human immune system. They explain how antigenic drift and shift impact vaccine development, highlighting potential vulnerabilities to flu pandemics.
Researchers found a link between CCR5 mutation and increased risk of severe West Nile virus infection. Individuals with this mutation had higher rates of symptomatic cases, highlighting potential implications for HIV treatment.
Researchers solved the structure of a viral harpoon protein, revealing its role in viral entry and fusion with host cells. The discovery sheds light on how viruses hijack cellular machinery to produce and spread more virus, and may lead to new treatments for infections caused by enveloped RNA viruses.
Researchers at NIAID identified a specific protein involved in resistance to the TB drug PA-824. By pinpointing this protein, scientists can develop improved versions of PA-824 and accelerate TB drug development.
The Fluarix clinical study demonstrated the vaccine's ability to induce protective antibodies, making it a promising tool in bolstering flu vaccine supply. The successful collaboration between academia, industry, and government agencies enabled the rapid development of the vaccine.
Occupational exposure to pigs significantly increases the risk of developing swine influenza infection, according to a new study. The risk is particularly high for farmers, veterinarians, and meat processing workers, who may be more likely to contract the virus due to their close contact with pigs.
Researchers found that combination of three microbicide gels provided protection against HIV-like virus in 20 out of 20 monkeys, with all three monkeys remaining virus-free. The study's findings are encouraging for the development of a microbicide for use in women.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $47 million to develop medical countermeasures against radiological and nuclear threats. Eight universities have received grants to establish centers for medical countermeasures against radiation, focusing on basic and applied research to develop new products...
A 2.5-year study involving 2,781 individuals aged 15-65 found the acellular pertussis vaccine to be safe and 92% effective in preventing the disease among adults and adolescents. The vaccine's effectiveness could help reduce transmission of the disease.
A new study shows that home-based environmental interventions can significantly reduce asthma symptoms and healthcare costs in children. The program, which targeted six major allergen classes, resulted in a 19% decrease in unscheduled clinic visits and a 13% reduction in albuterol inhaler use.
The experimental vaccine combines synthetically modified elements of four HIV genes found in subtypes A, B and C, representing about 85% of HIV infections worldwide. The trial aims to test the safety and ability of the vaccine to generate an immune response in healthy adults.
Researchers sequenced over 200 human flu strains, revealing a surprisingly large degree of genetic diversity and dynamic evolution. The study provides insights into why the 2003-04 flu vaccine provided partial protection against that season's flu.
Researchers have discovered a synthetic protein, P60 PLAD, that powerfully inhibits arthritis symptoms in mice. The study suggests that this protein could represent an advantage over current treatments, which directly block tumor necrosis factor alpha by binding to both TNFRs and inhibiting beneficial actions mediated by TNFR-2.
The National Institute of Allergy and Infectious Diseases has awarded $60 million to support the development of new tularemia vaccines. This contract is part of a larger NIAID biodefense awards package, which includes funding for Regional Biocontainment Laboratories and research on high-priority pathogens such as anthrax and smallpox.
Researchers have discovered a novel mechanism used by tick-borne flaviviruses to counteract the natural ability of interferon to combat the virus. The study found that NS5 protein blocks immune defenses, preventing the immune system from stopping the spread of the virus and helping the body recover from infection.
Community-acquired methicillin-resistant S. aureus (MRSA) strains have been found to evade the human immune system, leading to more severe infections in otherwise healthy individuals. The study identified specific genes that may control the bacteria's ability to escape neutrophil destruction.
Researchers found that small prions are significantly more infectious than large ones, yet there is a lower size limit beyond which infectivity is lost. The study's findings suggest that treatments targeting large prion deposits may do more harm than good by releasing the most infectious particles.
A telephone survey of over 3,500 US adults found conflicting attitudes towards HIV vaccine research. The survey revealed that some groups have misconceptions about vaccines and the importance of diverse participation in clinical trials.
The new partnership between NIAID and IPM aims to accelerate the development of effective microbicides, with a focus on enhancing formulation optimization, process development, and scale-up for manufacture. Large-scale effectiveness trials of five candidate microbicides are currently underway.
Researchers discovered specific mutations in the TACI gene that are associated with common variable immunodeficiency and IgA deficiency. These genetic defects impair the immune system's ability to fight infections, increasing the risk of recurrent illnesses and autoimmune diseases.
Researchers tested oseltamivir on mice infected with H5N1 virus, finding that higher doses for longer periods improved survival rates. The study suggests that antiviral drugs like oseltamivir may be effective in preventing and treating avian flu.
The NIAID-funded CHAVI center will focus on understanding early stages of HIV infection, developing new research tools, and designing improved HIV vaccines. The center aims to accelerate the development of a safe and effective preventive vaccine for HIV/AIDS through collaborative research.
The sequencing of three deadly parasite genomes has revealed a core of 6,200 genes in common among the parasites, providing new targets for drug development. This discovery also highlights the potential for designing targeted vaccines and improved diagnostics for each parasite.